Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 705

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 705
---
9 | % |     |      57.8 | % |     |     90.6 | % |
| Respiratory       |     |      |     |     55.9 | % |     |      21.9 | % |     |      64.5 | % |     |     95.6 | % |
| Psychiatry        |     |      |     |     52.7 | % |     |      26.8 | % |     |      56.3 | % |     |     91.2 | % |
| Endocrine         |     |      |     |     43.3 | % |     |      26.6 | % |     |      66.2 | % |     |     86.3 | % |
| Neurology         |     |      |     |     47.7 | % |     |      26.8 | % |     |      53.1 | % |     |     86.7 | % |
| Oncology          |     |      |     |     48.8 | % |     |      24.6 | % |     |      47.7 | % |     |     92.0 | % |
| Cardiovascular    |     |      |     |     50.0 | % |     |      21.0 | % |     |      55.2 | % |     |     82.5 | % |
| Urology           |     |      |     |     40.9 | % |     |      15.0 | % |     |      69.2 | % |     |     84.6 | % |

As can be seen, the success rates of clinical trials differ according to the disease area and according to the phase. The average success rates are represented by “All Indication” in which the probability of success of Phase I is 52% and those of Phase II and Phase III are 28.9% and 57.8% respectively. For the IsletRx (diabetes) development we used the Endocrine success rates from the above table.

| Moore Financial Consulting |

____________ 5Clinical Development Success rates and Contributing factors 2011–2020/BIO, February 2021 Annex E-25

Another one of the BIO research results is the rates of success of clinical trials for rare diseases.